title: Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer.
abstract: OBJECTIVE
  To evaluate the feasibility, toxicity and efficacy of the combination of low-dose cisplatin (CDDP) and gemcitabine (GEM) in elderly patients with advanced non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  This phase II trial included 46 patients aged 70 years or older with previously untreated advanced NSCLC. All patients were evaluable for response and toxicity. Treatment consisted of CDDP 50 mg/m(2) on day 1 plus GEM 1000 mg/m(2) on days 1 and 8. The regimen was repeated every 21 days. Patients received a minimum of three courses unless progressive disease was detected.
  
  
  RESULTS
  A total of 190 GEM-CDDP courses were administered (median 4.1 courses per patient). The chemotherapy regimen was well tolerated. No patients developed grade 4 toxicity. Grade 3 toxicities were as follows: neutropenia in six patients (13%), and anemia, thrombopenia and nausea/vomiting in one (2%) each. Two patients (4%) had mild nephrotoxicity. Of the 46 patients, 16 had a partial response (35%, 95% confidence interval, CI, 28-52%), 17 (37%) remained stable and 13 (28%) had disease progression. Eastern Cooperative Oncology Group performance status improved in 17 patients (37%), whereas 25 (54%, 95% CI 44-74%) showed a clinical benefit. Median time to progression was 20 weeks. Overall median survival was 44 weeks, with a 1-year actuarial survival rate of 35%.
  
  
  CONCLUSIONS
  The combination of low-dose CDDP and GEM for elderly patients with advanced NSCLC is an effective and well-tolerated chemotherapeutic approach.
authors.affiliation: Service of Medical Oncology, Hospital La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain. Jaimefeliu@hotmail.com
authors.forename: J
authors.initials: J
authors.lastname: Feliu
authors.forename: G
authors.initials: G
authors.lastname: Martín
authors.forename: C
authors.initials: C
authors.lastname: Madroñal
authors.forename: A
authors.initials: A
authors.lastname: Rodríguez-Jaráiz
authors.forename: J
authors.initials: J
authors.lastname: Castro
authors.forename: A
authors.initials: A
authors.lastname: Rodríguez
authors.forename: T
authors.initials: T
authors.lastname: Checa
authors.forename: M
authors.initials: M
authors.lastname: Bolaño
authors.forename: E
authors.initials: E
authors.lastname: Casado
authors.forename: M
authors.initials: M
authors.lastname: González-Barón
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D015897:Comorbidity; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine